Antifungal activity of Bacillus velezensis Y6 peptide against Candida albicans

Abstract

Abstract: Objective To study the inhibitory activity of Bacillus velezensis Y6 metabolite against C. albicans and its mechanism. Methods The inhibitory activity of Bacillus velezensis Y6 fermentation supernatant against C. albicans was studied by plate combined with Oxford cup. The minimum inhibitory concentration (MIC) was determined by gradient dilution method. The active components of the metabolites were screened by TLC. At the same time, the changes in the amount of intracellular macromolecules released and the intake of fluorescent dye PI before and after the treatment of antimicrobial peptides were compared to investigate the effect of antimicrobial peptides on membrane permeability. Results Bacillus velezensis Y6 metabolite could effectively inhibit the growth of C.albicans. When the test concentration was 10 mg·mL^-1, the inhibition zone diameter reached (38.2±0.5) mm, and the MIC concentration was 0.625 mg·mL^-1. Two antimicrobial components were found in the metabolites of Y6 by TLC. The main active component appears purple when encountering ninhydrin,so it may be peptide. The release of intracellular macromolecules and the intake of PI in C. albicans treated with antimicrobial peptides were significantly higher than those in the control group, indicating that the antimicrobial peptides of strain Y6 had a certain damage effect on the integrity of the membrane of C. albicans. Conclusion Bacillus velezensis Y6 produces peptide antifungal substances, which can damage the cell membrane of C.albicans, resulting in obvious antimicrobial activity.

Key words: Bacillus velezensis, Candida albicans, antifungal peptide, antimicrobial activity

CLC Number:

R379.4

YANG Cheng, QIAO Yunlong, LI Rongyu, XIONG Yanjing, TANG Xingli. Antifungal activity of Bacillus velezensis Y6 peptide against Candida albicans[J]. Chinese Journal of Mycology, 2022, 17(3): 183-187,194.

References

[1] SARDI J C O, SCORZONI L, BERNARDI T, et al. Candida species:currentepidemiology, pathogenicity, biofilm formation, natural antifungal productsand new therapeutic options[J]. J Med Microbiol. 2013,62(Pt 1):10-24.
[2] TALAPKO J, JUZBAŠIć M, MATIJEVIć T, et al. Candida albicans-The virulence factors and clinical manifestations of infection[J]. J Fungi,2021,7(2):79-79.
[3] CHENG S C, JOOSTEN L A, KULLBERG B J, et al.Interplay between Candida albicans and the mammalian innate host defense[J]. Infect Immun,2012,80(4):1304-1313.
[4] 李力翠,朱敬先,张国强,等.恶性肿瘤患者合并深部真菌感染研究进展[J].中国老年学杂志,2015,35(14):4071-4073.
[5] 陈锴,鲁仁义,阎澜.白念珠菌致病因素及抗真菌药物研究进展[J].中国真菌学杂志, 2017, 12(3):180-183.
[6] 买佳,王静.常用抗深部真菌感染药物及真菌对其耐药机制的研究进展[J].中国感染与化疗杂志,2015,15(4):395-398.
[7] 于晓佳,周虹,崔向丽,等.注射用两性霉素B致肝损害的药学监护[J].中国临床药理学杂志, 2017,33(15):1475-1476,1490.
[8] 叶健魁,王艳丽,宗峰,等.侵袭性真菌感染治疗药物研究进展[J].药学进展,2017,41(11):864-871.
[9] 朱丽芳,李强.深部真菌感染研究进展[J].现代医药卫生, 2017, 33(16):2484-2487.
[10] MATSUZAKI K. Control of cell selectivity of antimicrobial peptides[J]. Biochim Biophys Acta, 2009, 1788(8):1687-1692.
[11] 曹小红,廖振宇,王春林,等. Bacillus natto TK-1产脂肽的纯化、抑菌活性及其表面活性剂特性[J].中国生物工程杂志,2008,28(1):44-48.[12] 程群仙,孙褔琴,吴方方,等.一株抗真菌毛霉的分离鉴定及其抗菌活性检测[J].皖南医学院学报,2016,35(3):294-296.[13] 郭娟,贠建民,邓展瑞,等.Bacillus pumilus HN-10抗菌肽P-1对粉红单端孢的抑菌机理[J].食品科,2019,40(19):17-22.[14] 蔡蜨,李心丹,邓丽莉,等.抗菌肽PAF26对采后李果实褐腐菌的抑菌效果及机理[J].食品科学,2020, 41(23):7.[15] SHIRTLIFF M E, KROM B P, MEIJERING R A M, et al. Farnesol-induced apoptosis in Candida albicans[J]. Antimicrob Agents Chemother, 2009, 53(6):2392-2401.[16] 张丹丹,刘磊,唐艳,等.昆虫抗真菌肽的作用机制与应用研究进展[J].动物医学进展,2017,37(7):74-77.[17] KOVALCHUK L V, GANKOVSKAYA L V, GANKOVSKAYA O A, et al. Herpes simplex virus:treatment with antimicrobial peptides[J]. Adv Exp Med Bio,2007,601:369-376.DOI:10.1007/978-0-387-72005-0_39.